Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis.
Francesca PalandriMassimo BrecciaMassimiliano BonifacioNicola PolverelliElena M ElliGiulia BenevoloMario TiribelliElisabetta AbruzzeseAlessandra IurloFlorian H HeidelMicaela BergamaschiAlessia TieghiMonica CrugnolaFrancesco CavazziniGianni BinottoAlessandro IsidoriNicola SgherzaCostanza BosiBruno MartinoRoberto LatagliataGiuseppe AuteriLuigi ScaffidiDavide GriguoloMalgorzata TrawinskaDaniele CattaneoLucia CataniMauro KramperaRoberto M LemoliAntonio CuneoGianpietro SemenzatoRobin FoàFrancesco Di RaimondoDaniela BartolettiMichele CavoGiuseppe A PalumboNicola VianelliPublished in: Cancer (2019)
The survival of patients with myelofibrosis after discontinuation of ruxolitinib is poor, particularly for those who discontinue in blast phase. Salvage therapies can improve outcome, emphasizing the need for novel therapies.
Keyphrases